retatrutide liver Experimental weight-loss drug slashed fat in livers of obese people Retatrutide is being talked about

The Yale MeSH Analyzer

The primary outcome measure being assessed was the change in HbA1c from baseline to the end of treatment at week 32, while seconday outcome measures were related to endpoints of continuous glucose monitoring included time in range and time aboe range [2]

10.1016/j.nut.2021.111217 184

Neuber, T

GLP-1Ra at doses intended for T2D management Studies have examined the risk of fracture in both obese and non-obese individuals taking GLP-1Ra at doses intended for T2D (such as liraglutide 1.2 mg daily versus 3.0 mg daily for obesity) [75,76,77]

There is also the possibility of adverse interaction between antioxidant treatment and agents that do not act via an oxidative mechanism (e.g., 5-fluorouracil or tamoxifen)